OBJECTIVE： To systematically review the efficacy and safety of Compound kushen injection combined with oxaliplatin-based chemotherapy regimen in the treatment of colorectal cancer， and provide evidence-based reference for clinic. METHODS： Retrieved from CJFD， Wanfang Database， CBM， VIP， PubMed and Cochrane Library，randomized controlled trials （RCT） about Compound kushen injection combined with oxaliplatin-based chemotherapy （test group） versus conventional chemotherapy （control group） in the treatment of colorectal cancer were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation by modified Jadad scale. RESULTS： Totally 33 RCTs were included， involving 2 801 patients. Results of Meta-analysis showed the short-term effective rate [RR＝1.34，95％CI（1.24，1.46），P＜0.001]， improvement rate of KPS score[RR＝1.87，95％CI（1.65，2.14），P＜0.001]， CD4+/CD8+ values [WMD＝0.49，95％CI（0.26，0.72），P＜0.001]，CD4+ level[WMD＝10.34，95％CI（7.00，13.69），P＜0.001]，CD3+ level[WMD＝5.85，95％CI（4.07，7.62），P＜0.001]、nature kill cell level [WMD＝3.52，95％CI（1.76，5.27），P＜0.001]、IL-2 level [WMD＝12.96，95％CI（10.39，15.53），P＜0.001] in test group were significantly higher than control group， CD8+ level[WMD＝－5.89，95％CI（－11.39，－0.40），P＝0.04]，IL-10 level [WMD＝－21.04，95％CI（－29.15，－12.94），P＜0.001]，the incidence of nausea and vomiting [RR＝0.72，95％CI（0.67，0.78），P＜0.001]，white blood cell reduction [RR＝0.52，95％CI（0.45，0.61），P＜0.001]，abnormal liver function [RR＝0.63，95％CI（0.53，0.74），P＜0.001]，peripheral neurotoxicity [RR＝0.77，95％CI（0.64，0.92），P＜0.001] was significantly lower than control group， with statistical significances. CONCLUSIONS： Compound kushen injection combined with oxaliplatin-based chemotherapy is superior to conventional chemotherapy alone in the treatment of colorectal cancer， which can improve life quality and immune functions， reduce the adverse reactions induced by chemotherapy.